- Home
- NBR vs BCYC Comparison
NBR vs BCYC Comparison
Compare NBR & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBR
- BCYC
- Stock Information
- Founded
- NBR 1952
- BCYC 2009
- Country
- NBR Bermuda
- BCYC United Kingdom
- Employees
- NBR N/A
- BCYC N/A
- Industry
- NBR Oil & Gas Production
- BCYC Biotechnology: Pharmaceutical Preparations
- Sector
- NBR Energy
- BCYC Health Care
- Exchange
- NBR Nasdaq
- BCYC Nasdaq
- Market Cap
- NBR 445.2M
- BCYC 511.4M
- IPO Year
- NBR N/A
- BCYC 2019
- Fundamental
- Price
- NBR $29.83
- BCYC $8.42
- Analyst Decision
- NBR Hold
- BCYC Buy
- Analyst Count
- NBR 7
- BCYC 8
- Target Price
- NBR $71.17
- BCYC $29.14
- AVG Volume (30 Days)
- NBR 458.9K
- BCYC 445.4K
- Earning Date
- NBR 04-29-2025
- BCYC 05-05-2025
- Dividend Yield
- NBR N/A
- BCYC N/A
- EPS Growth
- NBR N/A
- BCYC N/A
- EPS
- NBR N/A
- BCYC N/A
- Revenue
- NBR $2,930,126,000.00
- BCYC $35,275,000.00
- Revenue This Year
- NBR $13.65
- BCYC N/A
- Revenue Next Year
- NBR $8.29
- BCYC $0.27
- P/E Ratio
- NBR N/A
- BCYC N/A
- Revenue Growth
- NBR N/A
- BCYC 30.76
- 52 Week Low
- NBR $25.11
- BCYC $6.10
- 52 Week High
- NBR $105.96
- BCYC $28.67
- Technical
- Relative Strength Index (RSI)
- NBR 40.78
- BCYC 51.30
- Support Level
- NBR $27.14
- BCYC $8.26
- Resistance Level
- NBR $30.25
- BCYC $9.52
- Average True Range (ATR)
- NBR 3.15
- BCYC 0.67
- MACD
- NBR 0.31
- BCYC 0.31
- Stochastic Oscillator
- NBR 59.97
- BCYC 67.84
About NBR Nabors Industries Ltd.
Nabors Industries Ltd owns and operates land-based drilling rig fleets and is a provider of offshore platform rigs in the United States and international markets. It also provides performance tools, directional drilling services, tubular running services, and technologies. The company has four reportable segments: U.S. Drilling, International Drilling, Drilling Solutions, and Rig Technologies. The key revenue of the company is generated from International Drilling.
About BCYC Bicycle Therapeutics plc
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.